PTGX Protagonist Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTGX

Price (delayed)

$103.01

Market cap

$6.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$6.44B

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 29

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 ...

Highlights
The quick ratio has grown by 39% from the previous quarter and by 6% YoY
The debt has declined by 14% year-on-year and by 5% since the previous quarter
Protagonist Therapeutics's revenue has shrunk by 64% YoY but it has surged by 61% QoQ
PTGX's gross profit has plunged by 64% YoY but it has soared by 61% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protagonist-inc.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PTGX

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
7.97%
1 week
2.59%
1 month
3.51%
1 year
99.9%
YTD
17.94%
QTD
-2.27%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$74.06M
Gross profit
$74.06M
Operating income
-$142.47M
Net income
-$114.71M
Gross margin
100%
Net margin
-154.9%
Protagonist Therapeutics's revenue has shrunk by 64% YoY but it has surged by 61% QoQ
PTGX's gross profit has plunged by 64% YoY but it has soared by 61% from the previous quarter
The net margin has grown by 45% since the previous quarter
The operating margin has grown by 44% from the previous quarter

Price vs fundamentals

How does PTGX's price correlate with its fundamentals

Growth

What is Protagonist Therapeutics's growth rate over time

Valuation

What is Protagonist Therapeutics stock price valuation
PTGX P/E details
P/E
N/A
P/B
10.03
P/S
90.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.96
Protagonist Therapeutics's EPS has increased by 12% QoQ
The P/B is 102% more than the 5-year quarterly average of 4.6 and 21% more than the last 4 quarters average of 7.7
The equity has grown by 7% from the previous quarter but it has contracted by 4.9% YoY
Protagonist Therapeutics's revenue has shrunk by 64% YoY but it has surged by 61% QoQ
The stock's price to sales (P/S) is 34% more than its last 4 quarters average of 62.6 but 21% less than its 5-year quarterly average of 105.5

Efficiency

How efficient is Protagonist Therapeutics business performance
Protagonist Therapeutics's return on sales has increased by 45% QoQ
The company's return on equity rose by 11% QoQ
PTGX's ROA is up by 10% since the previous quarter
The ROIC has grown by 6% from the previous quarter

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
The current ratio is up by 40% since the previous quarter and by 2.9% year-on-year
The quick ratio has grown by 39% from the previous quarter and by 6% YoY
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% from the previous quarter and by 50% YoY
The debt has declined by 14% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.